Health & Biotech
ASX Health Stocks: Island to tackle deadly Ebola virus
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape
ASX Health Stocks: Immuron gives vicious cycle kick in the guts
Neurotech forms expert panel after TGA meeting
ASX Health Stocks: Imricor installs key equipment at Swiss hospital
ScoPo’s Powerplays: ASX health stocks end the week ahead despite freaky inflation data
ASX Health Stocks: Microba completes autoimmune disease discovery program with NYSE-listed Ginkgo
ASX Health Stocks: Immutep sinks 35pc despite positive results from cancer-treatment trial
Race Oncology’s lead drug passes key GLP studies
ASX Health Stocks: Cleo gains FDA momentum for its ovarian cancer detection tech
The ASX biotechs with secured FDA clearances in 2024, and others looking likely
EZZ US bound after FDA approval for nine products
ASX Health Stocks: GTG’s GeneType Test can identify 80pc of people with risk of serious disease
InteliCare raises $2m to convert robust pipeline
ASX Health Stocks: Proteomics to start selling in France; Recce to start clinical trials
ASX wellness stocks offering calm and anxiety relief – Part 2
ScoPo’s Powerplays: ASX health stocks rise as M&A activity heats up
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.